This provider's $11.1M in total Medicare payments ranks in the 91th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 48144% from 2018 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 21691% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2018 | $299.63 | $177.63 | 1.69x | $122.00 | $22.7K | 128 | 2 |
| 2019 | $299.54 | $159.20 | 1.88x | $140.34 | $32.6K | 205 | 2 |
| 2021 | $193.83 | $40.33 | 4.81x | $153.50 | $38.8K | 962 | 4 |
| 2022 | $189.60 | $39.36 | 4.82x | $150.24 | $50.3K | 1.3K | 3 |
| 2023 | $51.88 | $39.30 | 1.32x | $12.58 | $11.0M | 279.2K | 6 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 59.8K | $4.4M | $73.51 | 1.38x |
| 86328 | Test for detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody, qualitative or semiquantitative | 59.1K | $2.6M | $44.37 | 1.13x |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 59.5K | $2.1M | $34.62 | 1.46x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 59.8K | $1.5M | $24.50 | 1.30x |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 42.5K | $500.0K | $11.76 | 1.70x |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 190 | $46.0K | $241.98 | 1.24x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 699 | $16.3K | $23.30 | 8.56x |
| 80307 | Testing for presence of drug | 143 | $9.4K | $65.72 | 4.55x |
This provider submits charges 1.35 times higher than what Medicare actually pays.
A markup ratio of 1.35x means for every $100 Medicare pays, this provider initially charges $135. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NC for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Burlington, NC | $2.2B | ⚠️ Flagged |
| Pathgroup Labs, Llc | Greensboro, NC | $203.7M | ⚠️ Flagged |
| Mako Medical Laboratories, Llc | Raleigh, NC | $107.0M | ✓ Clear |
| Quest Diagnostics Clinical Laboratories Inc | Greensboro, NC | $69.3M | ⚠️ Flagged |
| Laboratory Corporation Of America Holdings | Research Triangle Park, NC | $65.4M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data